MX2022010449A - Métodos de inhibición de masp-2 para el tratamiento y/o prevención del síndrome de dificultad respiratoria aguda inducido por coronavirus. - Google Patents
Métodos de inhibición de masp-2 para el tratamiento y/o prevención del síndrome de dificultad respiratoria aguda inducido por coronavirus.Info
- Publication number
- MX2022010449A MX2022010449A MX2022010449A MX2022010449A MX2022010449A MX 2022010449 A MX2022010449 A MX 2022010449A MX 2022010449 A MX2022010449 A MX 2022010449A MX 2022010449 A MX2022010449 A MX 2022010449A MX 2022010449 A MX2022010449 A MX 2022010449A
- Authority
- MX
- Mexico
- Prior art keywords
- masp
- coronavirus
- respiratory distress
- distress syndrome
- acute respiratory
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title abstract 7
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 title abstract 3
- 241000711573 Coronaviridae Species 0.000 title abstract 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 title abstract 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title 1
- 102100026046 Mannan-binding lectin serine protease 2 Human genes 0.000 abstract 7
- 101710117460 Mannan-binding lectin serine protease 2 Proteins 0.000 abstract 7
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 230000000153 supplemental effect Effects 0.000 abstract 2
- 208000025721 COVID-19 Diseases 0.000 abstract 1
- 241001678559 COVID-19 virus Species 0.000 abstract 1
- 208000001528 Coronaviridae Infections Diseases 0.000 abstract 1
- 206010035664 Pneumonia Diseases 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 230000024203 complement activation Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 150000003384 small molecules Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Electrostatic Separation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062986566P | 2020-03-06 | 2020-03-06 | |
| US202063008540P | 2020-04-10 | 2020-04-10 | |
| US202063015299P | 2020-04-24 | 2020-04-24 | |
| US202063054298P | 2020-07-21 | 2020-07-21 | |
| US202063062843P | 2020-08-07 | 2020-08-07 | |
| US202063104229P | 2020-10-22 | 2020-10-22 | |
| US202063105637P | 2020-10-26 | 2020-10-26 | |
| US202163140591P | 2021-01-22 | 2021-01-22 | |
| PCT/US2021/021217 WO2021178902A1 (fr) | 2020-03-06 | 2021-03-05 | Procédés d'inhibition de masp -2 pour le traitement et/ou la prévention du syndrome de détresse respiratoire aiguë induite par le coronavirus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022010449A true MX2022010449A (es) | 2022-11-16 |
Family
ID=77614472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022010449A MX2022010449A (es) | 2020-03-06 | 2021-03-05 | Métodos de inhibición de masp-2 para el tratamiento y/o prevención del síndrome de dificultad respiratoria aguda inducido por coronavirus. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210292436A1 (fr) |
| EP (1) | EP4114522A4 (fr) |
| JP (1) | JP2023516727A (fr) |
| KR (1) | KR20220152554A (fr) |
| CN (1) | CN115335120A (fr) |
| AU (1) | AU2021231892A1 (fr) |
| BR (1) | BR112022016991A2 (fr) |
| CA (1) | CA3169034A1 (fr) |
| IL (1) | IL296240A (fr) |
| MX (1) | MX2022010449A (fr) |
| TW (2) | TW202319069A (fr) |
| WO (1) | WO2021178902A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112237630A (zh) * | 2020-02-21 | 2021-01-19 | 中国人民解放军军事科学院军事医学研究院 | 针对masp-2、冠状病毒n蛋白或其结合的物质在制备冠状病毒所致疾病药物中的应用 |
| CN112023045A (zh) * | 2020-03-31 | 2020-12-04 | 中国人民解放军军事科学院军事医学研究院 | 抑制masp-2及其下游补体活化效应的物质在制备冠状病毒所致疾病药物中的应用 |
| WO2023174039A1 (fr) * | 2022-03-18 | 2023-09-21 | Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. | Anticorps ciblant masp-2 et leurs utilisations |
| WO2024081269A1 (fr) * | 2022-10-10 | 2024-04-18 | Dixit Rohan | Combinaisons thérapeutiques et méthodes de traitement de covid longue |
| WO2024118840A1 (fr) | 2022-11-30 | 2024-06-06 | Omeros Corporation | Pyrimidines fusionnées en tant qu'inhibiteurs de masp-2 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060002937A1 (en) * | 2004-06-10 | 2006-01-05 | University Of Leicester | Methods for treating conditions associated with MASP-2 dependent complement activation |
| KR102024016B1 (ko) * | 2011-05-04 | 2019-11-04 | 오메로스 코포레이션 | Masp-2 의존적 보체 활성화를 억제하는 조성물 |
| KR20220100997A (ko) * | 2012-06-18 | 2022-07-18 | 오메로스 코포레이션 | 다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법 |
| EA201500526A1 (ru) * | 2012-11-13 | 2015-12-30 | Общество С Ограниченной Ответственностью "Биогениус | Композиции и методы лечения воспалительных заболеваний инфекционного и неинфекционного происхождения |
| CA3099753A1 (fr) * | 2018-05-29 | 2019-12-05 | Omeros Corporation | Inhibiteurs de masp -2 et procedes d'utilisation |
| KR20210024003A (ko) * | 2018-06-22 | 2021-03-04 | 오메로스 코포레이션 | 다양한 혈전성 질환 및 장애의 치료를 위한 masp-2 억제 조성물 및 방법 |
| CN112237630A (zh) * | 2020-02-21 | 2021-01-19 | 中国人民解放军军事科学院军事医学研究院 | 针对masp-2、冠状病毒n蛋白或其结合的物质在制备冠状病毒所致疾病药物中的应用 |
| CN112023045A (zh) * | 2020-03-31 | 2020-12-04 | 中国人民解放军军事科学院军事医学研究院 | 抑制masp-2及其下游补体活化效应的物质在制备冠状病毒所致疾病药物中的应用 |
-
2021
- 2021-03-03 TW TW112103343A patent/TW202319069A/zh unknown
- 2021-03-03 TW TW110107578A patent/TWI834025B/zh active
- 2021-03-05 AU AU2021231892A patent/AU2021231892A1/en active Pending
- 2021-03-05 US US17/194,054 patent/US20210292436A1/en active Pending
- 2021-03-05 EP EP21764370.9A patent/EP4114522A4/fr active Pending
- 2021-03-05 IL IL296240A patent/IL296240A/en unknown
- 2021-03-05 MX MX2022010449A patent/MX2022010449A/es unknown
- 2021-03-05 CA CA3169034A patent/CA3169034A1/fr active Pending
- 2021-03-05 CN CN202180019367.6A patent/CN115335120A/zh active Pending
- 2021-03-05 KR KR1020227034690A patent/KR20220152554A/ko active Search and Examination
- 2021-03-05 BR BR112022016991A patent/BR112022016991A2/pt unknown
- 2021-03-05 WO PCT/US2021/021217 patent/WO2021178902A1/fr active Application Filing
- 2021-03-05 JP JP2022553016A patent/JP2023516727A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4114522A4 (fr) | 2024-05-01 |
| BR112022016991A2 (pt) | 2022-12-06 |
| KR20220152554A (ko) | 2022-11-16 |
| JP2023516727A (ja) | 2023-04-20 |
| CA3169034A1 (fr) | 2021-09-10 |
| WO2021178902A1 (fr) | 2021-09-10 |
| EP4114522A1 (fr) | 2023-01-11 |
| CN115335120A (zh) | 2022-11-11 |
| IL296240A (en) | 2022-11-01 |
| AU2021231892A1 (en) | 2022-10-20 |
| TWI834025B (zh) | 2024-03-01 |
| TW202319069A (zh) | 2023-05-16 |
| US20210292436A1 (en) | 2021-09-23 |
| TW202146047A (zh) | 2021-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022010449A (es) | Métodos de inhibición de masp-2 para el tratamiento y/o prevención del síndrome de dificultad respiratoria aguda inducido por coronavirus. | |
| Lupu et al. | Crosstalk between the coagulation and complement systems in sepsis | |
| Zhang et al. | Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy | |
| JP2020002171A5 (fr) | ||
| NO20021830L (no) | Sammensetninger egnet til å forhindre og behandle forkjölelse og influensaliknende symptomer samt fremgangsmåter vedfremstilling derav | |
| JP2016516073A5 (fr) | ||
| EA201891853A1 (ru) | Способы лечения или предотвращения атеросклероза путем введения ингибитора angptl3 | |
| Tamura et al. | Excretions/secretions from medicinal larvae (Lucilia sericata) inhibit complement activation by two mechanisms | |
| MX2022011231A (es) | Inhibidor de cxcr4 para el tratamiento del sindrome de dificultad respiratoria aguda e infecciones virales. | |
| JP2019519584A5 (fr) | ||
| AU2009246603A8 (en) | Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction | |
| EA202192528A1 (ru) | Комбинация ингибиторов pd-1 и ингибиторов lag-3 для повышения эффективности при лечении рака | |
| BR112022024662A2 (pt) | Métodos para tratamento ou prevenção de infecções por sars-cov-2 e covid-19 com anticorpos de glicoproteína spike anti-sars-cov-2 | |
| MX2022000545A (es) | Inhibidores de enzimas. | |
| WO2010023195A3 (fr) | Compositions et procédés pour le traitement du cancer | |
| MX2022010960A (es) | Métodos y composiciones para tratar el trastorno por uso de cannabis y mitigar la abstinencia de cannabinoides. | |
| MX2021006654A (es) | Uso de extracto de cocculus hirsutus para tratar dengue. | |
| Smithies et al. | Role of the tissue factor pathway in the pathogenesis and management of multiple organ failure | |
| Meijers | No contact, no thrombosis? | |
| MX2023006704A (es) | Composiciones dsg2 y metodos para el tratamiento de covid-19. | |
| Gerdin et al. | Pulmonary Insufficiency in the Rat after Intravascular Coagulation and Inhibition of Fibrinolysis: I. Studies on Some Pathogenetic Mechanisms | |
| EA202000298A1 (ru) | ПРОТИВОКОРОНАВИРУСНОЕ СРЕДСТВО ДЛЯ КОМБИНИРОВАННОЙ ТЕРАПИИ COVID-19 (SARS-CoV-2) И СПОСОБ ЛЕЧЕНИЯ | |
| MX2022000232A (es) | Composiciones y metodos para tratar o evitar infecciones oculares con filociclovir. | |
| EA202290048A1 (ru) | Лекарственное средство и его применение для лечения бактериальных инфекций, связанных с биопленкой | |
| MX2022006574A (es) | Uso de un anticuerpo anti-factor xii para el tratamiento o la prevencion del angioedema hereditario. |